TrialThe Lancet. Oncology2013

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.

John C Araujo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.